Economic Times | Roche, Prothena enter pact to co-develop & market antibodies for Parkinson's ... pharmabiz.com Roche and clinical stage biotechnology company, Prothena Corporation have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of ... Roche, Prothena to develop new antibodies for Parkinson's disease treatment Roche and Prothena to Devlop Antibodies for Parkinson's Disease Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co ... |
